2 completed, 2 terminated. 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow donafenib: new trials by email Literature Review of donafenib trials Research Report on donafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. HAIC, TACE, FOLFOX - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Terminated | Peking University | 18 | 2021-12-24 | 2025-12-18 |
| A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer Donafenib, Placebo - Differentiated Thyroid Cancer | Phase 3 | Terminated | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 204 | 2018-08-29 | 2021-12-13 |
| Donafenib for Previously Treated Metastatic Colorectal Cancer Donafenib, Placebo - Metastatic Colorectal Cancer | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 536 | 2016-12-28 | 2022-11-29 |
| Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma Donafenib, Sorafenib - HCC | Phase 2 / Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 668 | 2016-03-01 | 2020-01-09 |
Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1)
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (3) · Peking University (1)
China (4)
Bi Feng, MD (1) · Feng Bi, MD (1) · Lin Yan Song, MD (1) · Shukui Qin, MD (1) · Xiaodong Wang, MD (1) · Xu Jianming, MD (1)